- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03681379
Pharmacokinetics of Levosimendan in Pediatric Intensive Care Units (PALMAréa)
September 21, 2018 updated by: Nantes University Hospital
Pharmacokinetics of Levosimendan, OR1855 and OR1896 in Neonates and Children With or Without Extracorporeal Membrane Oxygenation
To describe pharmacokinetics of levosimendan in neonates and children supported or not with extracorporeal circulation devices (ECMO, CRRT)
Study Overview
Status
Unknown
Conditions
Detailed Description
Levosimendan is a calcium sensitiver wih inotropic effects.
It's use in the context of acute or chronic heart failure in children has yet to be defined.
Due to physical proprieties of levosimendan and metabolites, we hypothesized that concomitant use of extracorporeal devices such as ECMO will cause major pharmacokinetic variations.
Furthermore, pharmacokinetics of levosimendan in children with multiple organ failure has to be specify.
Study Type
Observational
Enrollment (Anticipated)
20
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Nantes, France
- CHU de Nantes
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 18 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
children admitted in pediatric intensive care units for acute heart failure
Description
Inclusion Criteria:
- All children admitted in pediatric intensive care units with planned infusion of 0.2 mcg/kg/min of levosimendan over 24h in context of routine care
- Arterial line or central venous catheter inserted for blood sampling procedures in context of routine care.
Exclusion Criteria:
- Absence of clear parental status or information
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
First parameter of the pharmacokinetics of levosimendan, OR1855, OR1896 (Area under the plasma concentration versus time curve (AUC) )
Time Frame: At the end of the study, after 2 years.
|
Area under the plasma concentration versus time curve (AUC) of levosimendan, OR 1855 and OR 1896.
Samples will be collected over a period in of 192h in context of routine care
|
At the end of the study, after 2 years.
|
second parameter of the pharmacokinetics of levosimendan, OR1855, OR1896 (distribution volume)
Time Frame: At the end of the study, after 2 years.
|
distribution volume of levosimendan, OR 1855 and OR 1896.
Samples will be collected over a period in of 192h in context of routine care
|
At the end of the study, after 2 years.
|
third parameter of the pharmacokinetics of levosimendan, OR1855, OR1896 (half-life time)
Time Frame: At the end of the study, after 2 years.
|
half-life time of levosimendan, OR 1855 and OR 1896.
Samples will be collected over a period in of 192h in context of routine care
|
At the end of the study, after 2 years.
|
fourth parameter of the pharmacokinetics of levosimendan, OR1855, OR1896 (Peak Plasma Concentration (Cmax))
Time Frame: At the end of the study, after 2 years.
|
Peak Plasma Concentration (Cmax) of levosimendan, OR 1855 and OR 1896.
Samples will be collected over a period in of 192h in context of routine care
|
At the end of the study, after 2 years.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
October 1, 2018
Primary Completion (Anticipated)
October 1, 2020
Study Completion (Anticipated)
October 1, 2020
Study Registration Dates
First Submitted
September 18, 2018
First Submitted That Met QC Criteria
September 21, 2018
First Posted (Actual)
September 24, 2018
Study Record Updates
Last Update Posted (Actual)
September 24, 2018
Last Update Submitted That Met QC Criteria
September 21, 2018
Last Verified
September 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RC16_0114
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Heart Failure
-
Idorsia Pharmaceuticals Ltd.CompletedAcute Heart Failure | Acute Decompensation of Chronic Heart Failure | New Onset of Heart FailureUnited States, United Kingdom, Israel, Switzerland, Austria, Denmark, France, Germany, Greece, Poland
-
Idorsia Pharmaceuticals Ltd.CompletedAcute Heart Failure | Acute Decompensation of Chronic Heart Failure | New Onset of Heart FailureUnited States, Hungary, Australia, Czechia, Germany, Italy, Norway, United Kingdom
-
Abiomed Inc.RecruitingHeart Diseases | Acute Decompensated Heart Failure | Congestive Heart Failure | Acute Heart FailureUnited States
-
Shanghai Chest HospitalUnknownAcute Renal Failure | Acute Heart FailureChina
-
Magenta Medical Ltd.TerminatedCongestive Heart Failure | Heart Failure, Congestive | Acute Heart FailureCroatia, Belgium, Serbia
-
University Medical Center GroningenCompletedHeart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteNetherlands
-
Jordan Cardio Vascular Research GroupRecruitingHeart Failure | Chronic Heart Failure | Acute Heart FailureJordan
-
Azienda Ospedaliera Città della Salute e della...Caretek S.r.l. Turin, Italy; Santer Reply S.p.A. Milan, ItalyUnknownHeart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteItaly
-
Clinica Alemana de SantiagoNot yet recruitingDecompensated Heart Failure | Heart Failure Acute
-
Adrian HernandezTerminatedDecompensated Heart Failure | Acute Heart FailureUnited States